Goldman Sachs’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-16,831
| Closed | -$40.2K | – | 7037 |
|
|
2025
Q4 | $40.2K | Sell |
16,831
-8,171
| -33% | -$20.1K | ﹤0.01% | 6304 |
|
|
2025
Q3 | $66.5K | Sell |
25,002
-87,082
| -78% | -$258K | ﹤0.01% | 6140 |
|
|
2025
Q2 | $333K | Buy |
112,084
+64,902
| +138% | +$189K | ﹤0.01% | 5384 |
|
|
2025
Q1 | $153K | Sell |
47,182
-6,548
| -12% | -$22.6K | ﹤0.01% | 5696 |
|
|
2024
Q4 | $212K | Buy |
53,730
+13,312
| +33% | +$90.7K | ﹤0.01% | 5624 |
|
|
2024
Q3 | $312K | Buy |
40,418
+27,252
| +207% | +$179K | ﹤0.01% | 5281 |
|
|
2024
Q2 | $67.7K | Sell |
13,166
-48,995
| -79% | -$378K | ﹤0.01% | 5441 |
|
|
2024
Q1 | $505K | Buy |
+62,161
| New | +$356K | ﹤0.01% | 4742 |
|
|
2022
Q3 | – | Sell |
-10,102
| Closed | -$57K | – | 6560 |
|
|
2022
Q2 | $57K | Sell |
10,102
-48,125
| -83% | -$324K | ﹤0.01% | 6003 |
|
|
2022
Q1 | $503K | Buy |
58,227
+16,739
| +40% | +$168K | ﹤0.01% | 5314 |
|
|
2021
Q4 | $462K | Sell |
41,488
-15,269
| -27% | -$199K | ﹤0.01% | 5438 |
|
|
2021
Q3 | $735K | Buy |
56,757
+29,183
| +106% | +$465K | ﹤0.01% | 4960 |
|
|
2021
Q2 | $456K | Buy |
27,574
+15,449
| +127% | +$262K | ﹤0.01% | 5277 |
|
|
2021
Q1 | $208K | Sell |
12,125
-452
| -4% | -$8.44K | ﹤0.01% | 5620 |
|
|
2020
Q4 | $197K | Sell |
12,577
-176
| -1% | -$3.24K | ﹤0.01% | 5100 |
|
|
2020
Q3 | $243K | Sell |
12,753
-19,992
| -61% | -$345K | ﹤0.01% | 4834 |
|
|
2020
Q2 | $449K | Sell |
32,745
-90,626
| -73% | -$1.27M | ﹤0.01% | 4434 |
|
|
2020
Q1 | $1.31M | Buy |
123,371
+104,153
| +542% | +$1.7M | ﹤0.01% | 3569 |
|
|
2019
Q4 | $359K | Buy |
19,218
+9,127
| +90% | +$118K | ﹤0.01% | 4676 |
|
|
2019
Q3 | $106K | Sell |
10,091
-1,859
| -16% | -$15.1K | ﹤0.01% | 4953 |
|
|
2019
Q2 | $91K | Sell |
11,950
-69,367
| -85% | -$603K | ﹤0.01% | 4936 |
|
|
2019
Q1 | $896K | Buy |
81,317
+71,281
| +710% | +$578K | ﹤0.01% | 4126 |
|
|
2018
Q4 | $51K | Buy |
+10,036
| New | +$41.2K | ﹤0.01% | 5091 |
|
|
2018
Q3 | – | Sell |
-11,513
| Closed | -$52K | – | 5812 |
|
|
2018
Q2 | $52K | Sell |
11,513
-9,758
| -46% | -$44.1K | ﹤0.01% | 5351 |
|
|
2018
Q1 | $114K | Sell |
21,271
-56,504
| -73% | -$260K | ﹤0.01% | 5233 |
|
|
2017
Q4 | $306K | Buy |
77,775
+31,467
| +68% | +$132K | ﹤0.01% | 5166 |
|
|
2017
Q3 | $202K | Sell |
46,308
-33,946
| -42% | -$160K | ﹤0.01% | 5748 |
|
|
2017
Q2 | $377K | Sell |
80,254
-18,545
| -19% | -$178K | ﹤0.01% | 5314 |
|
|
2017
Q1 | $1.63M | Buy |
98,799
+24,434
| +33% | +$320K | ﹤0.01% | 3949 |
|
|
2016
Q4 | $753K | Buy |
74,365
+59,979
| +417% | +$798K | ﹤0.01% | 4702 |
|
|
2016
Q3 | $194K | Sell |
14,386
-37,862
| -72% | -$555K | ﹤0.01% | 5852 |
|
|
2016
Q2 | $1.09M | Buy |
+52,248
| New | +$754K | ﹤0.01% | 4111 |
|
|
2016
Q1 | – | Sell |
-13,848
| Closed | -$151K | – | 7356 |
|
|
2015
Q4 | $151K | Sell |
13,848
-39,614
| -74% | -$506K | ﹤0.01% | 5906 |
|
|
2015
Q3 | $799K | Buy |
+53,462
| New | +$936K | ﹤0.01% | 4691 |
|
Other funds holding XBIT
VCM
RC
BCM
VFT
Goldman Sachs's XBIT Position: Q1 2026 in Review
Goldman Sachs sold out of XBiotech (XBIT) in Q1 2026, closing a stake of 16,831 shares — an estimated $40.2K sold.
Goldman Sachs first reported a position in XBIT in Q3 2015 and held it in 34 quarters. The position peaked at $1.63M in Q1 2017. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.
- Goldman Sachs reported no remaining XBiotech position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 16,831 XBiotech shares in Q1 2026, an estimated $40.2K.
- Goldman Sachs first reported a position in XBiotech in Q3 2015 and held it in 34 quarters.
- Goldman Sachs's XBiotech position peaked at $1.63M in Q1 2017.
- 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.